Valence8 US’s VistaGen Therapeutics VTGN Stock Holding History

Valence8 US’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-34,376	Closed	-$103K	–	60
2024 Q3	$103K	Buy	+34,376	New	+$117K	0.04%	53

Other funds holding VTGN

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Valence8 US's VTGN Position: Q4 2024 in Review

Valence8 US sold out of VistaGen Therapeutics (VTGN) in Q4 2024, closing a stake of 34,376 shares — an estimated $103K sold.

Valence8 US first reported a position in VTGN in Q3 2024 and held it in 1 quarter. The position peaked at $103K in Q3 2024. 54 funds tracked by Wall St. Rank hold VTGN as of Q4 2024.

Valence8 US reported no remaining VistaGen Therapeutics position as of Q4 2024 after selling out during the quarter.
Valence8 US sold 34,376 VistaGen Therapeutics shares in Q4 2024, an estimated $103K.
Valence8 US first reported a position in VistaGen Therapeutics in Q3 2024 and held it in 1 quarter.
Valence8 US's VistaGen Therapeutics position peaked at $103K in Q3 2024.
54 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q4 2024.

Based on Valence8 US's 13F filing for Q4 2024, filed 12 Feb 2025.